 - Stage 1: 23 patients. If 4 patients had clinical benefit, an additional 32 patients were to be enrolled. Up to 3 additional patients with platelet-derived growth factor receptor, alpha polypeptide PDGFRA mutation were to be enrolled, regardless of the total study enrollment. 